A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema

被引：3

作者：

Petersen, Remy S. ^{[1
]}

Fijen, Laure M. ^{[1
]}

Apfelbacher, Christian ^{[2
]}

Magerl, Markus ^{[3
,4
,5
,6
]}

Weller, Karsten ^{[3
,4
,5
,6
]}

Aberer, Werner ^{[7
]}

Adatia, Adil ^{[8
]}

Audhya, Paul ^{[9
]}

Bara, Noemi-Anna ^{[10
]}

Betschel, Stephen ^{[11
]}

Boccon-Gibod, Isabelle ^{[11
]}

Bouillet, Laurence ^{[12
,14
]}

Brodszki, Nicholas ^{[13
]}

Busse, Paula J. ^{[15
]}

Buttgereit, Thomas ^{[3
,4
]}

Bygum, Anette ^{[16
]}

Cancian, Mauro ^{[17
]}

Craig, Timothy ^{[18
]}

Csuka, Dorottya ^{[19
]}

Farkas, Henriette ^{[19
]}

Fomina, Daria ^{[20
,21
,22
]}

Gil-Serrano, Johana ^{[23
,24
]}

Gompels, Mark ^{[25
]}

Fogelbach, Guillermo Guidos ^{[26
]}

Guilarte, Mar ^{[23
,24
]}

Hide, Michihiro ^{[27
]}

Kiani-Alikhan, Sorena ^{[28
]}

Kinaciyan, Tamar ^{[29
]}

Lenten, Annet ^{[30
,43
]}

Lleonart, Ramon ^{[31
]}

Longhurst, Hilary ^{[32
,33
]}

Lumry, William R. ^{[34
]}

Malbran, Alejandro ^{[35
]}

Malinauskiene, Laura ^{[33
]}

Campos, Juan J. Matta ^{[36
,37
]}

Mendivil, Joan ^{[38
]}

Nieto-Martinez, Sandra A. ^{[39
]}

Peter, Jonathan G. ^{[40
,41
]}

Porebski, Grzegorz ^{[42
]}

Reshef, Avner ^{[39
]}

Riedl, Marc ^{[44
]}

Valerieva, Anna ^{[45
,46
]}

Waserman, Susan ^{[47
]}

Maurer, Marcus ^{[3
,4
]}

Cohn, Danny M. ^{[3
,4
,5
]}

机构：

[1] Univ Amsterdam, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam UMC, Amsterdam, Netherlands

[2] Otto von Guericke Univ, Inst Social Med & Hlth Syst Res, Med Fac, Magdeburg, Germany

[3] Charite Univ Medi Berlin, Inst Allergol, Angioedema Ctr Reference & Excellence, Berlin, Germany

[4] Free Univ Berlin, Berlin, Germany

[5] Humboldt Univ, Berlin, Germany

[6] Fraunhofer Inst Translat Med & Pharmacol ITMP, Immunol & Allergol, Berlin, Germany

[7] Med Univ Graz, Dept Dermatol, Graz, Austria

[8] Univ Alberta, Dept Med, Div Pulm Med, Edmonton, AB, Canada

[9] KalVista Pharmaceut, Cambridge, MA USA

[10] Mediquest Clin Res Ctr, Romanian Hereditary Angioedema Expertise Ctr, Sangeorgiu De Mures, Romania

[11] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON, Canada

[12] CHU Grenoble Alpes, Natl Reference Ctr Angioedema CREAK, Angioedema Ctr Reference & Excellence, Echirolles, France

[13] Univ Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup,Grenoble INP,CHU Grenoble Alpes,TIMC, Grenoble, France

[14] Skane Univ Hosp, Childrens Hosp, Dept Pediat Immunol, Lund, Sweden

[15] Icahn Sch Med Mt Sinai, Div Allergy & Clin Immunol, New York, NY USA

[16] Univ Southern Denmark, Clin Inst, Odense, Denmark

[17] Univ Hosp Padua, Dept Syst Med, Padua, Italy

[18] Penn State Univ, Dept Med & Pediat, Allergy Asthma & Immunol Div, Hershey, PA USA

[19] Semmelweis Univ, Hungarian Angioedema Ctr Reference & Excellence, Dept Internal Med & Haematol, Budapest, Hungary

[20] Clin City Hosp 52, Urticaria Ctr Reference & Excellence, Moscow Res & Clin Ctr Allergy & Immunol, Moscow, Russia

[21] Sechenov Univ, Dept Clin Immunol & Allergol, Moscow, Russia

[22] Astana Med Univ, Dept Pulmonol, Astana, Kazakhstan

[23] Hosp Univ Vall dHebron, Allergy Sect Dept, Dept Internal Med, Barcelona, Spain

[24] Univ Autonoma Barcelona, Inst Recerca Vall dHebron, Allergy Dept, Allergy Res Unit, Barcelona, Spain

[25] North Bristol NHS Trust, Clin Immunol, Bristol, England

[26] Inst Politecn Nacl SEPI ENMH, Dept Immunol, Mexico City, Mexico

[27] Hiroshima City Hiroshima Citizens Hosp, Dept Dermatol, Hiroshima, Japan

[28] Royal Free London NHS Fdn Trust, London, England

[29] Med Univ Vienna, Dept Dermatol, Vienna, Austria

[30] Takeda Pharmaceut, Hoofddorp, Netherlands

[31] Hosp Univ Bellvitge, Inst Recerca IDIBELL LHospitalet Llobregat, Allergol Dept, Barcelona, Spain

[32] Univ Auckland, Dept Immunol, Auckland Dist Hlth Board, Auckland, New Zealand

[33] Univ Auckland, Dept Med, Auckland, New Zealand

[34] Univ Texas Hlth Sci Ctr, Allergy Div, Internal Med, Dallas, TX USA

[35] Asma Inmunol Clin, Unidad Alergia, Buenos Aires, Argentina

[36] Vilnius Univ, Clin Chest Dis Immunol & Allergol, Dept Pulmonol & Allergol, Med Fac,VUH Santaros Klin, Vilnius, Lithuania

[37] UMAE Hosp Especial CMNSXXI, Allergy & Clin Immunol Dept, IMSS, Mexico City, Mexico

[38] Pharvaris GmbH, Head Evidence & Outcomes Res, Zug, Switzerland

[39] Natl Inst Pediat, Genet Unit Nutr, Mexico City, Mexico

[40] Univ Cape Town, Groote Schuur Hosp, Div Allergy & Clin Immunol, Cape Town, South Africa

[41] Univ Cape, Allergy & Immunol Unit, Town Lung Inst, Cape Town, South Africa

[42] Jagiellonian Univ, Dept Clin & Environm Allergol, Med Coll, Krakow, Poland

[43] Barzilai Univ, Angioedema Ctr, Med Ctr, Ashqelon, Israel

[44] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA USA

[45] Med Univ Sofia, Dept Allergol, Sofia, Bulgaria

[46] Univ Hosp Alexandrovska, Angioedema Ctr Reference & Excellence Bulgaria, Sofia, Bulgaria

[47] McMaster Univ, Dept Med, Hamilton, ON, Canada

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2024年 / 12卷 / 06期

关键词：

Acute treatment; Consensus; Core outcome set; Delphi; Hereditary angioedema; Randomized controlled trial; Outcome; VALIDATION;

D O I：

10.1016/j.jaip.2024.04.007

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

BACKGROUND: Clinical trials investigating drugs for the acute treatment of hereditary angioedema attacks have assessed many different outcomes. This heterogeneity limits the comparability of trial results and may lead to selective outcome reporting bias and a high burden on trial participants. OBJECTIVE: To achieve consensus on a core outcome set composed of key outcomes that ideally should be used in all clinical efficacy trials involving the acute treatment of hereditary angioedema attacks. METHODS: We conducted a Delphi consensus study involving all relevant parties: patients with hereditary angioedema, hereditary angioedema expert clinicians and clinical researchers, pharmaceutical companies, and regulatory bodies. Two Internetbased survey rounds were conducted. In round 1, panelists indicated the importance of individual outcomes used in clinical trials on a 9 -point Likert scale. Based on these results, a core outcome set was developed and voted on by panelists in round 2. RESULTS: A total of 58 worldwide panelists completed both rounds. The fi rst round demonstrated high importance scores and substantial agreement among the panelists. In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of fi ve key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction. CONCLUSIONS: This international study obtained a high level of consensus on a core outcome set for the acute treatment of hereditary angioedema attacks, consisting of fi ve key outcomes. Crown Copyright (c) 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). (J Allergy Clin Immunol Pract 2024;12:1614-21)

引用

页码：1614 / 1621

页数：8

共 50 条

[41] Development of a core outcome set for clinical trials in facial aging: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
Daniel I. Schlessinger
Sanjana Iyengar
Arianna F. Yanes
Jill K. Henley
Hovik J. Ashchyan
Anastasia O. Kurta
Payal M. Patel
Umar A. Sheikh
Matthew J. Franklin
Courtney C. Hanna
Brian R. Chen
Sarah G. Chiren
Jochen Schmitt
Stefanie Deckert
Karina C. Furlan
Emily Poon
Ian A. Maher
Todd V. Cartee
Joseph F. Sobanko
Murad Alam
Trials, 18
[42] The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema
Maurer, Marcus
Aberer, Werner
Caballero, Teresa
Bouillet, Laurence
Grumach, Anete S.
Botha, Jaco
Andresen, Irmgard
Longhurst, Hilary J.
CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (09) : 1048 - 1058
[43] Protocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: the Epilepsy outcome Set for Effectiveness Trials Project (EPSET)
Mitchell, James W.
Noble, Adam
Baker, Gus
Batchelor, Rachel
Brigo, Francesco
Christensen, Jakob
French, Jacqueline
Gil-Nagel, Antonio
Guekht, Alla
Jette, Nathalie
Kalviainen, Reetta
Leach, John Paul
Maguire, Melissa
O'Brien, Terence
Rosenow, Felix
Ryvlin, Philippe
Tittensor, Phil
Tripathi, Manjari
Trinka, Eugen
Wiebe, Samuel
Williamson, Paula R.
Marson, Tony
TRIALS, 2022, 23 (01)
[44] Protocol for the development of an international Core Outcome Set for treatment trials in adults with epilepsy: the EPilepsy outcome Set for Effectiveness Trials Project (EPSET)
James W. Mitchell
Adam Noble
Gus Baker
Rachel Batchelor
Francesco Brigo
Jakob Christensen
Jacqueline French
Antonio Gil-Nagel
Alla Guekht
Nathalie Jette
Reetta Kälviäinen
John Paul Leach
Melissa Maguire
Terence O’Brien
Felix Rosenow
Philippe Ryvlin
Phil Tittensor
Manjari Tripathi
Eugen Trinka
Samuel Wiebe
Paula R. Williamson
Tony Marson
Trials, 23
[45] Consensus recommendations on the diagnosis and treatment of hereditary angioedema Hellenic Society of Angioedema
Germenis, A. E.
Kompoti, E.
Konstantinou, G. N.
Makris, M.
Manousakis, E.
Mikos, N.
Paraskevopoulos, J.
Speletas, M.
Stefanaki, E.
Farmaki, E.
Psarros, F.
ARCHIVES OF HELLENIC MEDICINE, 2024, 41 (03): : 404 - 417
[46] Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
Schlessinger, Daniel I.
Iyengar, Sanjana
Yanes, Arianna F.
Lazaroff, Jake M.
Godinez-Puig, Victoria
Chen, Brian R.
Kurta, Anastasia O.
Henley, Jill K.
Chiren, Sarah G.
Furlan, Karina C.
Schmitt, Jochen
Deckert, Stefanie
Poon, Emily
Sobanko, Joseph F.
Cartee, Todd V.
Alam, Murad
Maher, Ian A.
TRIALS, 2017, 18
[47] Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
Daniel I. Schlessinger
Sanjana Iyengar
Arianna F. Yanes
Jake M. Lazaroff
Victoria Godinez-Puig
Brian R. Chen
Anastasia O. Kurta
Jill K. Henley
Sarah G. Chiren
Karina C. Furlan
Jochen Schmitt
Stefanie Deckert
Emily Poon
Joseph F. Sobanko
Todd V. Cartee
Murad Alam
Ian A. Maher
Trials, 18
[48] Development of a core outcome set for clinical trials in squamous cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
Schlessinger, Daniel I.
Iyengar, Sanjana
Yanes, Arianna F.
Chiren, Sarah G.
Godinez-Puig, Victoria
Chen, Brian R.
Kurta, Anastasia O.
Schmitt, Jochen
Deckert, Stefanie
Furlan, Karina C.
Poon, Emily
Cartee, Todd V.
Maher, Ian A.
Alam, Murad
Sobanko, Joseph F.
TRIALS, 2017, 18
[49] Physical Rehabilitation Core Outcomes In Critical illness (PRACTICE): protocol for development of a core outcome set
Bronwen Connolly
Linda Denehy
Nicholas Hart
Natalie Pattison
Paula Williamson
Bronagh Blackwood
Trials, 19
[50] Development of a core outcome set for clinical trials in squamous cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
Daniel I. Schlessinger
Sanjana Iyengar
Arianna F. Yanes
Sarah G. Chiren
Victoria Godinez-Puig
Brian R. Chen
Anastasia O. Kurta
Jochen Schmitt
Stefanie Deckert
Karina C. Furlan
Emily Poon
Todd V. Cartee
Ian A. Maher
Murad Alam
Joseph F. Sobanko
Trials, 18

← 1 2 3 4 5 →